{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T03:42:36Z","timestamp":1786592556662,"version":"build-2736575974"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2007,8,1]],"date-time":"2007-08-01T00:00:00Z","timestamp":1185926400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Urol"],"published-print":{"date-parts":[[2007,8]]},"DOI":"10.1038\/ncpuro0860","type":"journal-article","created":{"date-parts":[[2007,8,2]],"date-time":"2007-08-02T16:32:24Z","timestamp":1186072344000},"page":"422-431","source":"Crossref","is-referenced-by-count":8,"title":["Acute urinary retention: medical management and the identification of risk factors for prevention"],"prefix":"10.1038","volume":"4","author":[{"given":"Jay","family":"Khastgir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azhar","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Speakman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"BFncpuro0860_CR1","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1136\/bmj.318.7188.921","volume":"318","author":"M Emberton","year":"1999","unstructured":"Emberton M and Anson K (1999) Acute urinary retention in men: an age old problem. BMJ 318: 921\u2013925","journal-title":"BMJ"},{"issue":"Suppl 2","key":"BFncpuro0860_CR2","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/j.1464-410X.2006.06100.x","volume":"97","author":"JM Fitzpatrick","year":"2006","unstructured":"Fitzpatrick JM and Kirby RS (2006) Management of acute urinary retention. BJU Int 97 (Suppl 2): 16\u201320","journal-title":"BJU Int"},{"key":"BFncpuro0860_CR3","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/S0090-4295(97)00717-6","volume":"51","author":"CJ Girman","year":"1998","unstructured":"Girman CJ  et al. (1998) Health-related quality of life associated with lower urinary tract symptoms in four countries. Urology 51: 428\u2013436","journal-title":"Urology"},{"key":"BFncpuro0860_CR4","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/S0090-4295(01)01506-0","volume":"59","author":"G Welch","year":"2002","unstructured":"Welch G  et al. (2002) Quality-of-life impact of lower urinary tract symptom severity: results from the Health Professionals Follow-up Study. Urology 59: 245\u2013250","journal-title":"Urology"},{"key":"BFncpuro0860_CR5","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/S0090-4295(02)02371-3","volume":"61","author":"M Emberton","year":"2003","unstructured":"Emberton M  et al. (2003) Benign prostatic hyperplasia: a progressive disease of ageing men. Urology 61: 267\u2013273","journal-title":"Urology"},{"key":"BFncpuro0860_CR6","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/0140-6736(91)90543-X","volume":"338","author":"WM Garraway","year":"1991","unstructured":"Garraway WM  et al. (1991) High prevalence of benign prostatic hypertrophy in the community. Lancet 338: 469\u2013471","journal-title":"Lancet"},{"key":"BFncpuro0860_CR7","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/S0022-5347(05)68271-7","volume":"162","author":"SJ Jacobsen","year":"1999","unstructured":"Jacobsen SJ  et al. (1999) Treatment for benign prostatic hyperplasia among community dwelling men: the Olmsted County study of urinary symptoms and health status. J Urol 162: 1301\u20131306","journal-title":"J Urol"},{"key":"BFncpuro0860_CR8","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/S0022-5347(17)49698-4","volume":"132","author":"SJ Berry","year":"1984","unstructured":"Berry SJ  et al. (1984) The development of human benign prostatic hyperplasia with age. J Urol 132: 474\u2013479","journal-title":"J Urol"},{"key":"BFncpuro0860_CR9","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/S0090-4295(02)01649-7","volume":"59","author":"CG Roehrborn","year":"2002","unstructured":"Roehrborn CG (2002) Reporting of acute urinary retention in BPH treatment trials: importance of patient follow-up after discontinuation and case definitions. Urology 59: 811\u2013815","journal-title":"Urology"},{"key":"BFncpuro0860_CR10","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/S0302-2838(02)00354-8","volume":"42","author":"KM Verhamme","year":"2002","unstructured":"Verhamme KM  et al. (2002) Incidence and prevalence of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in primary care\u2014the Triumph project. Eur Urol 42: 323\u2013328","journal-title":"Eur Urol"},{"key":"BFncpuro0860_CR11","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/S0022-5347(01)64508-7","volume":"158","author":"SJ Jacobsen","year":"1997","unstructured":"Jacobsen SJ  et al. (1997) Natural history of prostatism: risk factors for acute urinary retention. J Urol 158: 481\u2013487","journal-title":"J Urol"},{"key":"BFncpuro0860_CR12","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1046\/j.1464-410x.1998.00632.x","volume":"81","author":"R Pickard","year":"1998","unstructured":"Pickard R  et al. (1998) The management of men with acute urinary retention. National Prostatectomy Audit Steering Group. Br J Urol 81: 712\u2013720","journal-title":"Br J Urol"},{"key":"BFncpuro0860_CR13","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/S0022-5347(05)68563-1","volume":"162","author":"JB Meigs","year":"1999","unstructured":"Meigs JB  et al. (1999) Incidence rates and risk factors for acute urinary retention: The health professionals follow-up study. J Urol 162: 376\u2013382","journal-title":"J Urol"},{"key":"BFncpuro0860_CR14","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1159\/000019749","volume":"34","author":"AJ Lee","year":"1998","unstructured":"Lee AJ  et al. (1998) The natural history of untreated lower urinary symptoms in middle-aged and elderly men over a period of 5 years. Eur Urol 34: 325\u2013332","journal-title":"Eur Urol"},{"key":"BFncpuro0860_CR15","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/S1569-9056(03)80104-5","volume":"2","author":"M Dobrovits","year":"2003","unstructured":"Dobrovits M  et al. (2003) A longitudinal prospective study of men with mild symptoms of BOO treated with watchful waiting over 4 years. Eur Urol Suppl 2: 26","journal-title":"Eur Urol Suppl"},{"key":"BFncpuro0860_CR16","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/S0090-4295(94)80165-7","volume":"44","author":"CJ Girman","year":"1994","unstructured":"Girman CJ  et al. (1994) Natural history of prostatism: impact of urinary symptoms on quality of life in 2115 randomly selected community men. Urology 44: 825\u2013831","journal-title":"Urology"},{"key":"BFncpuro0860_CR17","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1046\/j.1464-410x.1999.00966.x","volume":"83","author":"P Trueman","year":"1999","unstructured":"Trueman P  et al. (1999) Prevalence of lower urinary tract symptoms and self-reported diagnosed 'benign prostatic hyperplasia' and their effect on quality of life in a community-based survey of men in the UK. BJU Int 83: 410\u2013415","journal-title":"BJU Int"},{"key":"BFncpuro0860_CR18","first-page":"819","volume":"6","author":"J Kawakami","year":"1999","unstructured":"Kawakami J and Nickel JC (1999) Acute urinary retention and surgery for benign prostatic hyperplasia: the patient's perspective. Can J Urol 6: 819\u2013822","journal-title":"Can J Urol"},{"key":"BFncpuro0860_CR19","first-page":"473","volume":"57","author":"P Teillac","year":"2002","unstructured":"Teillac P (2002) Benign prostatic hyperplasia: patients' perception of medical treatment and their expectations. Results of a French survey involving patients treated with finasteride [French]. Therapie 57: 473\u2013483","journal-title":"Therapie"},{"key":"BFncpuro0860_CR20","unstructured":"Watson V  et al. (2004) Eliciting preferences for benign prostatic hyperplasia medical treatment [abstract # 229]. Presented at the XIX EAU Congress, Vienna 2004"},{"key":"BFncpuro0860_CR21","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1056\/NEJM199802263380901","volume":"338","author":"JD McConnell","year":"1998","unstructured":"McConnell JD  et al. (1998) The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med 338: 557\u2013563","journal-title":"N Engl J Med"},{"key":"BFncpuro0860_CR22","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1056\/NEJMoa030656","volume":"349","author":"JD McConnell","year":"2003","unstructured":"McConnell JD  et al. (2003) The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 349: 2387\u20132398","journal-title":"N Engl J Med"},{"issue":"Suppl 2","key":"BFncpuro0860_CR23","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/j.1464-410X.2006.06098.x","volume":"97","author":"CG Roehrborn","year":"2006","unstructured":"Roehrborn CG (2006) Definition of at-risk patients: baseline variables. BJU Int 97 (Suppl 2): 7\u201311","journal-title":"BJU Int"},{"key":"BFncpuro0860_CR24","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/S0022-5347(01)62081-0","volume":"161","author":"C Kolman","year":"1999","unstructured":"Kolman C  et al. (1999) Distribution of post-void residual urine in randomly selected men. J Urol 161: 122\u2013127","journal-title":"J Urol"},{"key":"BFncpuro0860_CR25","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/S0022-5347(05)00041-8","volume":"175","author":"SA Kaplan","year":"2006","unstructured":"Kaplan SA  et al. (2006) Combination therapy with doxazosin and finasteride for benign prostatic hyperplasia in patients with lower urinary tract symptoms and a baseline total prostate volume of 25 ml or greater. J Urol 175: 217\u2013220","journal-title":"J Urol"},{"key":"BFncpuro0860_CR26","first-page":"241","volume":"171","author":"CG Roehrborn","year":"2004","unstructured":"Roehrborn CG  et al. (2004) Impact of baseline PSA and TRUS volume on longitudinal changes in IPSS and maximum flow rate in MTOPS [abstract #911]. J Urol 171: 241","journal-title":"J Urol"},{"key":"BFncpuro0860_CR27","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1111\/j.1464-410X.2006.06110.x","volume":"97","author":"CG Roehrborn","year":"2006","unstructured":"Roehrborn CG (2006) Alfuzosin 10 mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute retention: results of a 2-year placebo-controlled study. BJU Int 97: 734\u2013741","journal-title":"BJU Int"},{"issue":"Suppl","key":"BFncpuro0860_CR28","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/S0022-5347(18)35422-3","volume":"173","author":"CG Roehrborn","year":"2005","unstructured":"Roehrborn CG  et al. (2005) The impact of acute or chronic inflammation in baseline biopsy on the risk of clinical progression of BPH. Results from the MTOPS study. J Urol 173 (Suppl): 346","journal-title":"J Urol"},{"key":"BFncpuro0860_CR29","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1111\/j.1464-410X.2005.05761.x","volume":"96","author":"J Armitage","year":"2005","unstructured":"Armitage J and Emberton M (2005) Is it time to reconsider the role of prostatic inflammation in the pathogenesis of lower urinary tract symptoms? BJU Int 96: 745\u2013746","journal-title":"BJU Int"},{"issue":"Suppl 2","key":"BFncpuro0860_CR30","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/j.1464-410X.2006.06099.x","volume":"97","author":"M Emberton","year":"2006","unstructured":"Emberton M (2006) Definition of at-risk patients: dynamic variables. BJU Int 97 (Suppl 2): 12\u201315","journal-title":"BJU Int"},{"key":"BFncpuro0860_CR31","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.urology.2005.03.024","volume":"66","author":"M Emberton","year":"2005","unstructured":"Emberton M  et al. (2005) Symptom deterioration during treatment and history of AUR are the strongest predictors for AUR and BPH-related surgery in men with LUTS treated with alfuzosin 10 mg once daily. Urology 66: 316\u2013322","journal-title":"Urology"},{"key":"BFncpuro0860_CR32","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1161\/01.RES.78.5.737","volume":"78","author":"RM Graham","year":"1996","unstructured":"Graham RM  et al. (1996) Alpha 1-adrenergic receptor subtypes. Molecular structure, function, and signalling. Circ Res 78: 737\u2013749","journal-title":"Circ Res"},{"key":"BFncpuro0860_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000019919","volume":"36","author":"B Djavan","year":"1999","unstructured":"Djavan B and Marberger M (1999) A meta-analysis on the efficacy and tolerability of \u03b11 adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol 36: 1\u201313","journal-title":"Eur Urol"},{"key":"BFncpuro0860_CR34","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1016\/0140-6736(91)93140-5","volume":"337","author":"A Jardin","year":"1991","unstructured":"Jardin A  et al. (1991) Alfuzosin for treatment of benign prostatic hypertrophy. Lancet 337: 1457\u20131461","journal-title":"Lancet"},{"key":"BFncpuro0860_CR35","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/sj.pcan.4500253","volume":"5","author":"B Lukacs","year":"1998","unstructured":"Lukacs B  et al. (1998) Three-year prospective study of 3228 clinical BPH patients studied with alfuzosin in general practice. Prostate Cancer Prostatic Dis 5: 276\u2013293","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"BFncpuro0860_CR36","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S0090-4295(00)01021-9","volume":"57","author":"SA McNeill","year":"2001","unstructured":"McNeill SA  et al. (2001) Post-void residual urine in patients with LUTS suggestive of BPH: pooled analysis of eleven controlled studies with alfuzosin. Urology 57: 459\u2013465","journal-title":"Urology"},{"issue":"Suppl. 6","key":"BFncpuro0860_CR37","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1159\/000052594","volume":"39","author":"R. Hartung","year":"2001","unstructured":"Hartung R (2001) Do alpha-blockers prevent the occurrence of acute urinary retention? Eur Urol (Suppl 6): 13\u201318","journal-title":"European Urology"},{"key":"BFncpuro0860_CR38","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1016\/S0022-5347(01)63162-8","volume":"159","author":"N Kyprianou","year":"1998","unstructured":"Kyprianou N  et al. (1998) Induction of prostate apoptosis by doxazosin in benign prostatic hyperplasia. J Urol 159: 1810\u20131815","journal-title":"J Urol"},{"key":"BFncpuro0860_CR39","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1016\/S0022-5347(05)68873-8","volume":"161","author":"JK Chon","year":"1999","unstructured":"Chon JK  et al. (1999) Alpha 1-adrenoceptor antagonists terazosin and doxazosin induce prostate apoptosis without affecting cell proliferation in patients with benign prostatic hyperplasia. J Urol 161: 2002\u20132008","journal-title":"J Urol"},{"key":"BFncpuro0860_CR40","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1002\/pros.10357","volume":"59","author":"A Tahmatzopoulos","year":"2004","unstructured":"Tahmatzopoulos A and Kyprianou N (2004) Apoptotic impact of alpha1-blockers on prostate cancer growth: a myth or an inviting reality? Prostate 59: 91\u2013100","journal-title":"Prostate"},{"key":"BFncpuro0860_CR41","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1210\/jc.2003-030330","volume":"89","author":"RV Clark","year":"2004","unstructured":"Clark RV  et al. (2004) Marker suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5\u03b1-reductase inhibitor. J Clin Endocrinol Metab 89: 2179\u20132184","journal-title":"J Clin Endocrinol Metab"},{"key":"BFncpuro0860_CR42","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1159\/000020189","volume":"37","author":"CG Roehborn","year":"2000","unstructured":"Roehborn CG  et al. (2000) Urinary retention in patients with BPH treated with finasteride or placebo over 4 years. Eur Urol 37: 528\u2013536","journal-title":"Eur Urol"},{"key":"BFncpuro0860_CR43","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.eururo.2004.05.008","volume":"46","author":"F Debruyne","year":"2004","unstructured":"Debruyne F  et al. (2004) Efficacy and safety with long-term treatment with the dual 5\u03b1-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia. Eur Urol 46: 488\u2013494","journal-title":"Eur Urol"},{"issue":"Suppl","key":"BFncpuro0860_CR44","first-page":"169","volume":"2","author":"P Boyle","year":"2003","unstructured":"Boyle P  et al. (2003) The novel dual 5\u03b1-reductase inhibitor dutasteride is effective for the treatment and prevention of complications in men with a PV 30\u2013 \u226440 cc and 40 cc [abstract #632]. Eur Urol 2 (Suppl): 169","journal-title":"Eur Urol"},{"key":"BFncpuro0860_CR45","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1016\/S0022-5347(05)65189-0","volume":"167","author":"JJ de la Rosette","year":"2002","unstructured":"de la Rosette JJ  et al. (2002) Long-term risk of re-treatment of patients using \u03b1-blockers for lower urinary tract symptoms. J Urol 167: 1734\u20131739","journal-title":"J Urol"},{"key":"BFncpuro0860_CR46","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/S0302-2838(03)00367-1","volume":"44","author":"J Barkin","year":"2003","unstructured":"Barkin J  et al. (2003) Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5\u03b1-reductase inhibitor dutasteride. Eur Urol 44: 461\u2013466","journal-title":"Eur Urol"},{"issue":"Suppl","key":"BFncpuro0860_CR47","first-page":"7","volume":"77","author":"PS Chan","year":"1996","unstructured":"Chan PS  et al. (1996) Can terazosin (alpha blocker) relieve acute urinary retention and obviate the need for indwelling urinary catheter [abstract #26]. Br J Urol 77 (Suppl): 7","journal-title":"Br J Urol"},{"issue":"Suppl","key":"BFncpuro0860_CR48","first-page":"77","volume":"88","author":"E Bowden","year":"2001","unstructured":"Bowden E  et al. (2001) Tamsulosin in the treatment of urinary retention: a prospective, placebo-controlled trial [abstract #148]. BJU Int 88 (Suppl): 77","journal-title":"BJU Int"},{"key":"BFncpuro0860_CR49","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1111\/j.1464-410X.2005.05299.x","volume":"95","author":"MG Lucas","year":"2005","unstructured":"Lucas MG  et al. (2005) Tamsulosin in the management of patients in acute urinary retention from benign prostatic hyperplasia. BJU Int 95: 354\u2013357","journal-title":"BJU Int"},{"key":"BFncpuro0860_CR50","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.eururo.2003.10.001","volume":"45","author":"SA McNeill","year":"2004","unstructured":"McNeill SA (2004) The role of alpha-blockers in the management of acute urinary retention caused by benign prostatic obstruction. Eur Urol 45: 325\u2013332","journal-title":"Eur Urol"},{"key":"BFncpuro0860_CR51","doi-asserted-by":"publisher","first-page":"2316","DOI":"10.1097\/01.ju.0000127743.80759.7a","volume":"171","author":"SA McNeill","year":"2004","unstructured":"McNeill SA and Hargreave TB (2004) Alfuzosin once daily facilitates return to voiding in patients in acute urinary retention. J Urol 171: 2316\u20132320","journal-title":"J Urol"},{"key":"BFncpuro0860_CR52","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1111\/j.1464-410X.2006.06109.x","volume":"97","author":"F Desgrandchamps","year":"2006","unstructured":"Desgrandchamps F  et al. (2006) Management of acute urinary retention in France: a cross-sectional survey in 2618 men with benign prostatic hyperplasia. BJU Int 97: 727\u2013733","journal-title":"BJU Int"},{"key":"BFncpuro0860_CR53","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.urology.2004.07.042","volume":"65","author":"SA McNeill","year":"2005","unstructured":"McNeill SA  et al. (2005) Alfuzosin 10 mg once daily in the management of acute urinary retention: results of a double-blind placebo-controlled study. Urology 65: 83\u201390","journal-title":"Urology"}],"container-title":["Nature Clinical Practice Urology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/ncpuro0860.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ncpuro0860","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/ncpuro0860","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/ncpuro0860.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T20:16:59Z","timestamp":1684441019000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/ncpuro0860"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,8]]},"references-count":53,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2007,8]]}},"alternative-id":["BFncpuro0860"],"URL":"https:\/\/doi.org\/10.1038\/ncpuro0860","relation":{},"ISSN":["1743-4270","1743-4289"],"issn-type":[{"value":"1743-4270","type":"print"},{"value":"1743-4289","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,8]]}}}